Bonet-Roselló L, Martínez-Córdova Z

Idioma: Español
Referencias bibliográficas: 29
Paginas: 126-130
Archivo PDF: 90.97 Kb.

RESUMEN

Diferentes estudios han confirmado la influencia de la compatibilidad de los antígenos de leucocitos humanos (HLA) en la supervivencia del injerto, así como la fuerte asociación de estas moléculas con ciertas enfermedades. En los últimos años, se han desarrollado nuevos métodos de tipificación HLA basados en técnicas moleculares, las que ofrecen flexibilidad de resolución, reproducibilidad y exactitud superiores, al ser comparadas con los métodos serológicos tradicionales. El objetivo de esta revisión es comparar las técnicas serológicas y moleculares mostrando sus principios, ventajas y los resultados experimentales.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Howell WM, Navarrete C. The HLA System: an update and relevance to patient-donor matching strategies in clinical transplantation. Vox Sang 1996; 71: 6-12.

2. González-Molina M, Alonso A. Biología de la inmunosupresión. Barcelona: Novartis Farmacéutica SA. 1999.

3. McCluskey J, Au Peh C. The human leucocyte antigens and clinical medicine: an overview. Rev Immunogenetics 1999; 1: 3-20.

4. Giralt P, Urra JM, Sanabria C, Giralt J, Pérez MJ, Benito P. Biological differences on onset among type 1A diabetics in relation to HLA-DQ genetic markers. Med Clin (Barc) 2003; 120: 6-9.

5. Pascual M, Mataran L, Jones G, Shing D, van der Slik AR, Giphart MJ, et al. HLA haplotypes and susceptibility to rheumatoid arthritis. More than class II genes. Scand J Rheumatol 2002; 31: 275-278.

6. Patel R, Mickey MR, Terasaki PI. Serotyping for homotransplantation. XVI, analysis of kidney transplants from unrelated donors. N Engl J Med 1968; 279: 501-506.

7. Takemoto S, Terasaki PI, Cekca JM, Cho YW, Gjertson DW. Survival of nationally shared, HLA-matched kidney transplants from cadaveric donors. N Engl J Med 1992; 327: 834-839.

8. Opelz G. HLA matching in Asian recipients of kidney grafts from unrelated living or cadaveric donors. The Collaborative Transplant Study. Hum Immunol 2000; 61: 115-119.

9. Susal C, Opelz G. Kidney graft failure and presensitization against HLA class I and class II antigens. Transplantation 2002; 73: 1269-1273.

10. Terasaki PI, McClelland JD. Microdroplet assay of human serum cytotoxins. Nature 1964; 204: 998-1000.

11. Martin S, Dyer PA. Identification and importance of MHC. The definition of HLA specificities by cytotoxicity. Transplant Immunology 1994; 2: 108-115.

12. Colombe BW. Histocompatibility testing. In: Stites DP, Terr AI, Parslow TG (Eds). Basic & clinical immunology. 8a ed. USA: Appleton & Lange; 1994. p. 237-255.

13. Olerup O, Zetterquist H. HLA-DR typing by PCR amplification with sequence-specific primers (PCR-SSP) in 2 hours: an alternative to serological DR typing in clinical practice including donor-recipient matching in cadaveric transplantation. Tissue Antigens 1992; 39: 225-235.

14. Tiercy JM, Jeannet M, Mach B. A new approach for the analysis of HLA class II polymorphism: HLA oligotyping. Blood Rev 1990; 4: 9-15.

15. Middleton D. Identification of MHC-molecular biology. Transplant Immunology 1994; 2: 111-115.

16. Bettinotti MP, Mitsuishi Y, Bibee K, Lau M, Terasaki PI. Comprehensive method for the typing of HLA A, B and C alleles by direct sequencing of PCR products obtained from genomic DNA. J Immunother 1997; 20: 425-430.

17. Dyer PA, Jawaheer D, Ollier B, Poulton K, Sinnott P, Thomson W. HLA allele detection using molecular techniques. Disease Markers 1993; 11: 145-160.

18. Bunce M, O’Neill CM, Barnardo MC, Krausa P, Browning MJ. Phototyping: comprehensive DNA typing for HLA A, B, C, DRB1, DRB3, DRB4, DRB5 and DQB1 by PCR with 144 primer mixes utilizing sequence-specific primers (PCR-SSP). Tissue Antigens 1995; 46: 355-367.

19. Opelz G, Mytilineos J, Scherer S, Dunckley H, Trejaut J. Survival of DNA HLA-DR typed and matched cadaver kidney transplants. Collaborative Transplant Study. Lancet 1991; 338: 461-463.

20. Opelz G. Discrepancies between serological and DNA typing. Collaborative Transplant Study. Newsletter 3; 1992.

21. Mytilineos J, Lempert M, Middleton D, Williams F, Cullen C, Scherer S, et al. HLA class I DNA typing of 215 ‘HLA A, B, DR zero mismatched’ kidney transplants. Tissue Antigens 1997; 50: 355-358.

22. Nataf S, Hourmant MH, Herry P, Cesbron A, Bonneville F, Cheneau ML, et al. Kidney transplantation and HLA-DR compatibility evaluated by genomic analysis: one center study. Rev Fr Transfus Hemobiol 1993; 36: 179-189.

23. Adam K, Vavatsi N, Mytilineos J, Kouidou S, Polymenidis Z, Trakatellis A, et al. HLA class II DNA-RFLP typing in 102 individuals from Northern Greece. Transpl Int 1994; 7 (Suppl 1): S522-S526.

24. Schaffer M, Olerup O. HLA-AB typing by polymerase-chain reaction with sequence-specific primers: more accurate, less errors, and increased resolution compared to serological typing. Tissue Antigens 2001; 58: 299-307.

25. Tan J, Xie T, Xu Q. HLA-DR typing by standard serology and PCR amplification with sequence-specific primers: a comparative study. Zhonghua Yi Xue Za Zhi 1997; 77: 28-30.

26. Woszczek G, Borowiec M, Mis M, Gorska M, Kowalski ML. Comparison of serological and molecular (PCR-SSP) techniques of HLA-DR typing in clinical laboratory routine. Ann Transplant 1997; 2: 39-42.

27. Kulcsarova E, Kralovicova J, Parnicka Z, Ferencik S, Buc M. Comparison of the results of HLA typing using serologic and molecular genetics methods. Bratisl Lek Listy 2000; 101: 134-137.

28. Nelson JL, Mickelson S, Masewicz S. Dw14 (DRB1*0404) is a Dw4-dependent risk factor for rheumatoid arthritis: rethinking the ‘shared epitope’ hypothesis. Tissue Antigens 1991; 38: 145-151.

29. van der Linden S, van der Heijde D. Clinical aspects, outcome assessment, and management of ankylosing spondylitis and postenteric reactive arthritis. Curr Opin Rheumatol 2000; 12: 263-268.